Type II Secretory Phospholipase A2 and Prognosis in Patients with Stable Coronary Heart Disease: Mendelian Randomization Study
Open Access
- 22 July 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (7) , e22318
Abstract
Serum type II secretory phospholipase A2 (sPLA2-IIa) has been found to be predictive of adverse outcomes in patients with stable coronary heart disease. Compounds targeting sPLA2-IIa are already under development. This study investigated if an association of sPLA2-IIa with secondary cardiovascular disease (CVD) events may be of causal nature or mainly a matter of confounding by correlated cardiovascular risk markers. Eight-year follow-up data of a prospective cohort study (KAROLA) of patients who underwent in-patient rehabilitation after an acute cardiovascular event were analysed. Associations of polymorphisms (SNP) in the sPLA2-IIa-coding gene PLA2G2A with serum sPLA2-IIa and secondary fatal or non-fatal CVD events were examined by multiple regression. Hazard ratios (HR) were compared with those expected if the association between sPLA2-IIa and CVD were causal. The strongest determinants of sPLA2-IIa (rs4744 and rs10732279) were associated with an increase of serum concentrations by 81% and 73% per variant allele. HRs (95% confidence intervals) estimating the associations of the SNPs with secondary CVD events were increased, but not statistically significant (1.16 [0.89–1.51] and 1.18 [0.91–1.52] per variant allele, respectively). However, these estimates were very similar to those expected when assuming causality (1.18 and 1.17), based on an association of natural log-transformed sPLA2-IIa concentration with secondary events with HR = 1.33 per unit. The present findings regarding genetic polymorphisms, determination of serum sPLA2-IIa, and prognosis in CVD patients are consistent with a genuine causal relationship and thus might point to a valid drug target for prevention of secondary CVD events.Keywords
This publication has 27 references indexed in Scilit:
- Efficacy of Homocysteine-Lowering Therapy With Folic Acid in Stroke PreventionStroke, 2010
- Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart DiseaseJAMA, 2009
- Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular DiseaseCardiovascular Drugs and Therapy, 2009
- Lipoprotein-Associated and Secretory Phospholipase A2 in Cardiovascular Disease: The Epidemiological EvidenceCardiovascular Drugs and Therapy, 2008
- Mendelian Randomisation and Causal Inference in Observational EpidemiologyPLOS Medicine, 2008
- Inflammation, Insulin Resistance, and Diabetes—Mendelian Randomization Using CRP Haplotypes Points UpstreamPLOS Medicine, 2008
- Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and WomenArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Insight into the nature of the CRP–coronary event association using Mendelian randomizationInternational Journal of Epidemiology, 2006
- Homocysteine and stroke: evidence on a causal link from mendelian randomisationThe Lancet, 2005
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004